Kura Oncology KURA Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$294.57M-5.7% | -$278.67M-28.5% | -$216.88M-10.0% | -$197.17M-8.4% | -$181.89M-4.5% | ||
| $1.15M+11.0% | $1.03M+23.9% | $833K-5.0% | $877K+2.6% | $855K+0.8% | ||
| $37.68M+1.5% | $37.11M+7.9% | $34.39M+8.3% | $31.75M-4.5% | $33.23M-2.0% | ||
| $488K-5.2% | $515K-6.7% | $552K+1.3% | $545K+2.1% | $534K+2.1% | ||
| —— | —— | —— | —— | $48.23M+2,241% | ||
| $739.75K+79.1% | $413K+33.3% | $309.75K+50.0% | $206.5K+100% | $103.25K— | ||
| —— | —— | —— | —— | $4.64M+385% | ||
| —— | —— | —— | —— | $4.01M-76.2% | ||
| —— | —— | $26.32M+67.9% | $15.68M+175% | $5.7M-16.8% | ||
| $988K-5.3% | $1.04M-10.1% | $1.16M+8.1% | $1.07M+26.5% | $848K+11.9% | ||
| $162.51M-21.3% | $206.55M+72.4% | $119.8M-31.0% | $173.68M-28.6% | $243.23M-12.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $87.8M-29.8% | $124.99M+12.4% | $111.23M-17.2% | ||
| $6.47M-2.5% | $6.64M+41.6% | $4.69M+121% | $2.12M+212% | $680K+44.1% | ||
| $664.48M-12.8% | $761.59M-0.1% | $762.4M+11.2% | $685.63M-6.4% | $732.7M+11.2% | ||
| $735.03M-2.7% | $755.13M+4.4% | $723.63M+21.4% | $595.86M-4.8% | $625.72M+12.1% | ||
| —— | —— | —— | —— | —— | ||
| $1.72M-4.1% | $1.79M+22.4% | $1.47M-60.0% | $3.67M-40.8% | $6.19M-28.0% | ||
| —— | —— | —— | —— | —— | ||
| $1.72M-4.1% | $1.79M+22.5% | $1.46M-60.1% | $3.67M-40.8% | $6.19M-96.0% | ||
| —— | —— | —— | —— | $9.76M-94.8% | ||
| $6.73M-20.8% | $8.49M-15.0% | $9.99M-13.2% | $11.5M-8.2% | $12.53M-4.6% | ||
| $488K-5.2% | $515K-6.7% | $552K+1.3% | $545K+2.1% | $534K+2.1% | ||
| $1.15M+11.0% | $1.03M+23.9% | $833K-5.0% | $877K+2.6% | $855K+0.8% | ||
| —— | —— | —— | —— | $4.01M-76.2% | ||
| —— | —— | —— | —— | —— | ||
| $3.92M-38.4% | $6.36M+24.3% | $5.12M— | —— | —— | ||
| $988K-5.3% | $1.04M-10.1% | $1.16M+8.1% | $1.07M+26.5% | $848K+11.9% | ||
| —— | —— | $26.32M+67.9% | $15.68M+175% | $5.7M-16.8% | ||
| $664.48M-12.8% | $761.59M-0.1% | $762.4M+11.2% | $685.63M-6.4% | $732.7M+11.2% | ||
| $735.03M-2.7% | $755.13M+4.4% | $723.63M+21.4% | $595.86M-4.8% | $625.72M+12.1% | ||
| $1.72M-4.1% | $1.79M+22.4% | $1.47M-60.0% | $3.67M-40.8% | $6.19M-28.0% | ||
| $162.51M-21.3% | $206.55M+72.4% | $119.8M-31.0% | $173.68M-28.6% | $243.23M-12.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $83.11M-32.4% | $122.87M+11.1% | $110.55M-17.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kura Oncology generate?
- Kura Oncology (KURA) generated -$267.2M in operating cash flow over the trailing twelve months.
- What is Kura Oncology's free cash flow?
- After $6.5M of capital expenditures, Kura Oncology's free cash flow was -$271.6M over the trailing twelve months, down 302.9% year over year.
- Where does Kura Oncology's cash flow data come from?
- Every line is extracted from Kura Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
